What Happens to Your Insurance Program When Your Life Sciences Company Gets Acquired?

An acquisition does not transfer the target company’s insurance program to the acquirer. It triggers a sequence of policy events most founders do not anticipate, and several of them have to be addressed before close or the protection lapses at the worst possible moment. Change-of-control provisions can void coverage. Tail coverage requirements emerge the moment a claims-made policy is about to be canceled. The acquirer’s program may not respond to the target’s prior acts. Each gap surfaces exactly when the seller no longer controls anything to do about it.

Change of Control Is a Policy Event, Not Just a Corporate One

Many of the policies on a life sciences company’s program contain a change-of-control provision. Directors and officers liability, employment practices liability, and professional liability written on a claims-made basis are the most common, but the wording varies and is rarely the wording a founder remembers. The provision typically says that on a change of control, coverage for acts after the closing date is suspended unless the carrier consents, and the policy effectively converts to a run-off arrangement for acts before closing. If the change is not notified to the carrier and the run-off is not arranged, the post-closing coverage gap is real and the pre-closing coverage may also be compromised.

The reason is simple. The carrier underwrote the company that existed before the deal. After the deal, the company has new owners, possibly new directors, and a new exposure profile. The change-of-control provision lets the carrier consent to the new exposure, decline it, or negotiate new terms.

Tail Coverage Is the Specific Mechanism

For claims-made policies, the practical answer to change of control is a run-off endorsement, commonly called tail coverage. The endorsement extends the policy’s claims-made coverage for a defined period after the policy ends, so claims made during that period for acts before the policy ended are still covered. Without it, the moment the claims-made policy is canceled at close, any claim filed afterward for a pre-close act has no policy to attach to.

Tail length is a negotiated number, often six years for D&O in an acquisition context, though the specific term depends on the policy, the carrier, and the deal terms. The cost is paid up front and is usually borne by the seller out of the deal proceeds, which is why founders who have not priced tail before the negotiation start are surprised when the cost line item appears on the closing statement. The structural logic for a device company specifically is mapped in tail coverage for a medical device company, and the same logic applies across the life sciences program for any claims-made line.

The Acquirer’s Program Probably Does Not Reach Back

A founder who assumes the acquirer’s program will pick up the company at close discovers two limits on that. First, the acquirer’s policies were underwritten for the acquirer’s exposures, and adding the target as a new operating unit usually requires the acquirer’s carrier to consent, sometimes to re-rate, and sometimes to add or exclude specific exposures. Second, the acquirer’s program almost never covers the target’s prior acts. The target’s D&O claims from pre-close acts, the target’s professional liability claims for pre-close services, and the target’s clinical trial liability from pre-close studies all attach to the target’s pre-close policies, not the acquirer’s go-forward program. The tail is the bridge that keeps the pre-close program responsive for the period after close.

For a device company, the products liability dimension is usually different. Products liability on the standard form is occurrence-based, so the policy in effect at the time of injury responds regardless of when the claim is filed. The acquirer’s go-forward products program covers post-close injuries, the target’s pre-close products program covers pre-close injuries, and the seam is the date of injury rather than the date of claim. This is the same structural logic that makes the pre-close insurance review part of due diligence, because the policies decide who pays for what.

What Has to Happen Before Close

Three actions are non-negotiable. The first is identifying every change-of-control provision in the program and notifying each carrier on the timeline the policy requires. The second is structuring tail coverage on every claims-made policy for a term consistent with the statute of limitations applicable to the exposure (longer for D&O securities exposure than for short-tail lines). The third is reading the acquirer’s go-forward program and confirming how it will treat the target’s operations after close, including the prior-acts question and any exclusion the acquirer’s carrier requires before adding the target.

The fourth, often deferred, is reps and warranties insurance and how the program’s gaps map to its exclusions. R&W underwriters scrutinize the target’s insurance program; gaps the buyer might absorb otherwise become exclusions on the R&W policy, which become deal points the seller carries. The cleanest approach is to run a diligence-grade review of the program before the process opens, then walk into the negotiation with the gaps already addressed.

A specialty review through Tower Street Insurance can map a life sciences company’s insurance program against the structure of a pending acquisition, identify the change-of-control, tail, and prior-acts decisions on each line, and time the actions so the protection survives the close.